Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Recruiting target patients is intermittent making it impracticable to enroll the required study sample. The administrative responsibilities have been met with extraordinary challenges. Current funding does not match the incurring costs.

Conditions

Solid Cancer

Interventions

BIOLOGICAL: Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months

Sponsor

Oncovir, Inc.

Collaborators

[object Object]
[object Object]
[object Object]